ArticleDiscover oncology2025
PTX3 as a diagnostic and prognostic biomarker in lung adenocarcinoma: a comprehensive analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PTX3 induces the expression of PD-L1 and promotes breast cancer immune escape.Breast cancer (Tokyo, Japan) · 2026Article
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring.Frontiers in immunology · 2026Review
- Comprehensive multi-omics analysis reveals prognostic, immune, and therapeutic signatures of TNFAIP family genes in breast cancer.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer remains a leading global cause of mortality, with lung adenocarcinoma (LUAD) as the predominant histological subtype. Current serum biomarkers like carcinoembryonic antigen (CEA) lack specificity, necessitating novel diagnostic targets. Pentraxin 3 (PTX3), a homo-multimeric protein downregulated in malignancies, was evaluated for its diagnostic and prognostic roles in LUAD.
methodsPTX3 expression was analyzed using TCGA/GEO datasets and clinical serum samples (97 LUAD vs. 40 controls). Diagnostic utility was assessed via ROC curves for PTX3, CEACAM5, and their combination. Prognostic value was determined by Kaplan-Meier and Cox regression. PTX3-associated differentially expressed genes (DEGs) were explored through functional enrichment, tumor microenvironment (TME) analysis, and drug sensitivity profiling.
resultThe TCGA and GEO datasets revealed that PTX3 mRNA expression was significantly downregulated in LUAD, and the AUC values with PTX3 were > 0.7. Detection of CEACAM5 and PTX3 combined can improve diagnostic accuracy, and patients with high PTX3 level have shorter overall survival. Multivariate Cox analysis revealed that PTX3 is an independent predictor of overall survival. The result of ELISA further confirmed the low level of PTX3 protein. PTX3 is important in the functional analysis and TME of lung adenocarcinoma. In addition, the sensitivity of tumor cells to anti-cancer drugs is significantly correlated with the expression of PTX3.
conclusionPTX3 emerges as a dual biomarker for LUAD diagnosis and prognosis, with mechanistic ties to TME remodeling and therapeutic resistance, highlighting its potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.